ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ribupatide

Also written as “HRS9531”, “HRS9531 injection” and “HRS9531 Tablet”.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Kidney Failure, Chronic · Atherosclerosis · Fatty Liver, led by 2 companies.

Drug pageRibupatide: every studyAll 33 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 30, 202438 company-led studies, 19 open or runningLicense: Hengrui → Kailera, May 2024Next primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine3214 open or runningphase 3since Apr 30, 2024Nov 29, 2021Dec 2026phase 3 · NCT06994650
Kaileraits history only65 open or runningphase 3since Dec 9, 2025Jun 23, 2025May 2027phase 2 · NCT07458269
  • Named in Jiangsu HengRui Medicine’s own pipeline as Ribupatide, phase 4, as of Jul 31, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Jiangsu HengRui Medicine only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 18 earlier studies, Nov 29, 2021 to Dec 5, 2024.

  1. May 2024Kailera licensed it from HengruiLicenseEverywhere outside Greater China · agreed · Kailera Therapeutics (release)
  2. Jan 20, 2025Phase 1 study in OverweightNCT06792955 · 120 enrolled · China
  3. Feb 18, 2025Phase 2 study in Chronic Management of Body WeightNCT06841445 · 166 enrolled · China
  4. Feb 25, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT06855147 · 7 enrolled · China
  5. Apr 24, 2025Phase 3 study in Sleep Apnea, ObstructiveNCT06974851 · 140 planned · China
  6. May 20, 2025Phase 3 study in Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP TherapyNCT06994650 · 144 enrolled · China
  7. Jun 22, 2025Phase 3 study in Diabetes Mellitus, Type 2NCT07060456 · 300 planned · China
  8. Jul 10, 2025Named ribupatideINNProposed as its International Nonproprietary Name in WHO's List 133 · before, HRS9531
  9. Aug 27, 2025Phase 1 study in OverweightNCT07150962 · 168 planned · China
  10. Dec 3, 2025Phase 3 study in ObesityNCT07285902 · 572 enrolled · China
  11. Apr 13, 2026Phase 1 study in Diabetes MellitusNCT07540754 · 24 planned · China
  12. Apr 17, 2026Phase 3 study in AtherosclerosisNCT07551492 · 9,262 planned · China
  13. May 11, 2026Phase 2 study in T2DMNCT07599410 · 240 planned · China
  14. Jun 16, 2026Phase 2 study in Metabolic Dysfunction-Associated Steatohepatitis (MASH)NCT07660848 · 160 planned · China
  15. Jun 22, 2026Phase 3 study in Chronic Management of Body WeightNCT07670884 · 675 planned · China
  16. Jul 8, 2026Phase 3 study in Osteoarthritis, KneeNCT07709910 · 382 planned · China

Ahead

  1. Dec 2026Primary completion: phase 3 study in Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP TherapyNCT06994650
  2. Dec 2026Primary completion: phase 3 study in Sleep Apnea, ObstructiveNCT06974851
  3. Jan 2027Primary completion: phase 1 study in Diabetes MellitusNCT07540754
  4. Feb 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07060456

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 32 Jiangsu HengRui Medicine leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07709910Osteoarthritis, Knee · China3Not yet recruitingNov 2028382
NCT07670884Chronic Management of Body Weight · China3RecruitingOct 31, 2027675
NCT07660848Metabolic Dysfunction-Associated Steatohepatitis (MASH) · China2RecruitingMar 2028160
NCT07599410T2DM · China2RecruitingMay 2027240
NCT07551492Atherosclerosis · China3RecruitingMay 24, 20319,262
NCT07540754Diabetes Mellitus · China1RecruitingJan 202724
NCT07285902Obesity · China3Active, not recruitingMar 2027572
NCT07150962Overweight · China1RecruitingFeb 2026168
NCT07060456Diabetes Mellitus, Type 2 · China3RecruitingFeb 2027300
NCT06994650Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy · China3Active, not recruitingDec 2026144
NCT06974851Sleep Apnea, Obstructive · China3RecruitingDec 2026140
NCT06855147Diabetes Mellitus, Type 2 · China1CompletedJun 17, 20257
NCT06841445Chronic Management of Body Weight · China2CompletedJan 8, 2026166
NCT06792955Overweight · China1CompletedJun 6, 2025120
NCT06762600Overweight · China1CompletedMar 12, 2026102
NCT06723691Diabetes Mellitus, Type 2 · China1CompletedJun 9, 202557
NCT06654960Diabetes Mellitus, Type 2 · China1CompletedDec 26, 202420
NCT06650007Diabetes Mellitus, Type 2 · China3CompletedJan 21, 2026218
NCT06649344Diabetes Mellitus, Type 2 · China3CompletedJul 18, 2026884
NCT06595797Obese Subjects With Polycystic Ovary Syndrome (PCOS)2UNKNOWNDec 2025144
NCT06565871Weight Management2Not yet recruitingDec 2025108
NCT06506175Diabetes Mellitus, Type 2 · China1Not yet recruitingSep 2026100
NCT06435676Overweight · China1CompletedOct 8, 202472
NCT06396429Overweight · China3CompletedJul 7, 2025567
NCT06391710Heart Failure With Preserved Ejection Fraction · China2Active, not recruitingJan 2026203
NCT06246175Diabetes Mellitus, Type 2 · China1CompletedSep 2, 202532
NCT06054698Overweight · China2CompletedSep 9, 202461
NCT05966272Diabetes Mellitus, Type 2 · China2CompletedSep 24, 2024199
NCT05881837Overweight · China2CompletedOct 13, 2024249
NCT05893576Diabetes Mellitus, Type 2 · China1CompletedSep 4, 202350
NCT05516966Diabetes Mellitus, Type 2 · China1CompletedMay 24, 202364
NCT05152277Diabetes Mellitus, Type 2 · China1CompletedAug 24, 202290

How it is read

Names in the registry

  • “HRS9531”, 16 entries
  • “HRS9531 injection”, 14 entries
  • “HRS9531 Tablet”, 9 entries
  • “HRS9531 Injection”, 6 entries
  • “Ribupatide”, 5 entries

Codes read as this program: HRS9531.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.